Notably, the non-overlapping functions of VISTA and PD-1/PD-L1, along with their frequent co-expression, suggest that combining VISTA inhibitors with ICIs could synergistically enhance anti-tumour immune responses. Here, PDCD1 is linked to neoplasm.